VNDA · Vanda Pharmaceuticals Inc. · Webcasts, Transcripts & Audio
$4.64
-0.17 (-3.53%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$305.34M
Shares
60.46M
Volume · Oct 2
661.21K
Avg daily vol (3M)
949.54K
Vanda Pharmaceuticals Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Vanda Pharmaceuticals Inc. (VNDA), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼6.8%
$65.32M
$3.27M
'22 Q3
22-11-02
▼5.2%
$64.48M
$6.86M
'22 Q4
23-02-08
▲3.8%
$62.50M
$3.25M
'23 Q1
23-05-03
▼28.5%
$46.06M
$1.52M
'23 Q2
23-07-27
▼40.6%
$38.81M
$137,000
'23 Q3
23-11-08
▼29.8%
$45.27M
−$2.40M
'23 Q4
24-02-07
▼24.1%
$47.46M
−$4.15M
'24 Q1
24-05-08
▲9.6%
$50.47M
−$4.52M
'24 Q2
24-07-31
▲22.8%
$47.65M
−$5.32M
'24 Q3
24-11-06
▲17.5%
$53.19M
−$4.91M
'24 Q4
25-02-13
▲5.4%
$50.04M
−$29.49M
'25 Q1
25-05-07
▲4.2%
$52.59M
−$27.21M
'25 Q2
25-07-31
▲18.1%
$56.26M
−$22.59M
'25 Q3
25-10-29
▲7.6%
$57.22M
−$141.19M
'25 Q4
26-02-11
▲3.4%
$51.72M
−$48.57M
'26 Q1
26-05-06
LATEST
▼3.9%
$50.53M
−$62.51M
'26 Q2
26-08-05
Conference
Investor event
2026-09-15
Vanda Pharmaceuticals Inc. (VNDA) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-05
Vanda Pharmaceuticals Inc. (VNDA) Q2 2026 Earnings Call Transcript
Positive tone
Pipeline catalysts and readouts
GLP-1 adjunctive indication
Fanapt commercial growth
Revenue
$50.53M
▼ 3.9% YoY Diluted EPS
$-1.04
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-05-19
Vanda Pharmaceuticals Inc. (VNDA) May 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
Vanda Pharmaceuticals Inc. (VNDA) Q1 2026 Earnings Call Transcript
Confident tone
Fanapt commercial momentum
Dysanti (milsoperidone) approval and pipeline
Nirius launch and DTC platform
Revenue
$51.72M
▲ 3.4% YoY Diluted EPS
$-0.82
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-11
Vanda Pharmaceuticals Inc. (VNDA) Q4 2025 Earnings Call Transcript
Confident tone
Fanapt commercial growth
Tradipitant (Nereus) motion sickness approval and launch
2026 revenue guidance and pipeline catalysts
Revenue
$57.22M*
▲ 7.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-29
Vanda Pharmaceuticals Inc. (VNDA) Q3 2025 Earnings Call Transcript
Confident tone
Fanapt commercial growth and bipolar launch
PONVORY commercial buildout
HETLIOZ market share despite generics
Revenue
$56.26M
▲ 18.1% YoY Diluted EPS
$-0.38
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
Vanda Pharmaceuticals Inc. (VNDA) Q2 2025 Earnings Call Transcript
Confident tone
Fanapt growth and sales force expansion
Bysanti NDA and pipeline catalyst
PONVORY commercialization
Revenue
$52.59M
▲ 4.2% YoY Diluted EPS
$-0.46
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Vanda Pharmaceuticals Inc. (VNDA) Q1 2025 Earnings Call Transcript
Confident tone
Long-acting injectable development
Fanapt commercial growth
Pipeline and regulatory milestones
Revenue
$50.04M
▲ 5.4% YoY Diluted EPS
$-0.50
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-13
Vanda Pharmaceuticals Inc. (VNDA) Q4 2024 Earnings Call Transcript
Confident tone
Fanapt bipolar launch and growth
Vantrela / milsaperidone NDA
Ponvory MS launch and label expansion
Revenue
$53.19M*
▲ 17.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Vanda Pharmaceuticals Inc. (VNDA) Q3 2024 Earnings Call Transcript
Positive tone
Fanapt bipolar I launch and sales force build-out
PONVORY multiple sclerosis commercialization
Milsaperidone pipeline development
Revenue
$47.65M
▲ 22.8% YoY Diluted EPS
$-0.09
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-31
Vanda Pharmaceuticals Inc. (VNDA) Q2 2024 Earnings Call Transcript
Positive tone
Fanapt bipolar I approval and commercial expansion
PONVORY acquisition and MS launch
HETLIOZ generic erosion
Revenue
$50.47M
▲ 9.6% YoY Diluted EPS
$-0.08
▼ 366.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Vanda Pharmaceuticals Inc. (VNDA) Q1 2024 Earnings Call Transcript
Positive tone
Fanapt bipolar I approval and lifecycle
PONVORY acquisition and commercial transition
HETLIOZ franchise and challenges
Revenue
$47.46M
▼ 24.1% YoY Diluted EPS
$-0.07
▼ 216.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-07
Vanda Pharmaceuticals Inc. (VNDA) Q4 2023 Earnings Call Transcript
Balanced tone
HETLIOZ insomnia sNDA and FDA dispute
Generic competition and revenue
Tradipitant gastroparesis NDA
Revenue
$45.27M*
▼ 29.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Vanda Pharmaceuticals Inc. (VNDA) Q3 2023 Earnings Call Transcript
Revenue
$38.81M
▼ 40.6% YoY Diluted EPS
$0.00
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-07-27
Vanda Pharmaceuticals Inc. (VNDA) Q2 2023 Earnings Call Transcript
Revenue
$46.06M
▼ 28.5% YoY Diluted EPS
$0.03
▼ 40% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Vanda Pharmaceuticals Inc. (VNDA) Q1 2023 Earnings Call Transcript
Revenue
$62.50M
▲ 3.8% YoY Diluted EPS
$0.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-08
Vanda Pharmaceuticals Inc. (VNDA) Q4 2022 Earnings Call Transcript
Revenue
$64.48M*
▼ 5.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Vanda Pharmaceuticals Inc. (VNDA) Q3 2022 Earnings Call Transcript
Revenue
$65.32M
▼ 6.8% YoY Diluted EPS
$0.06
▼ 57.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Vanda Pharmaceuticals Inc. (VNDA) Q2 2022 Earnings Call Transcript
Revenue
$64.39M
▼ 5.2% YoY Diluted EPS
$0.05
▼ 70.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Vanda Pharmaceuticals Inc. (VNDA) Q1 2022 Earnings Call Transcript
Revenue
$60.19M
▼ 4% YoY Diluted EPS
$-0.11
▼ 173.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-23
Vanda Pharmaceuticals Inc. (VNDA) Q4 2021 Earnings Call Transcript
Revenue
$68.02M*
▲ 0.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Vanda Pharmaceuticals Inc. (VNDA) Q3 2021 Earnings Call Transcript
Revenue
$70.09M
▲ 16.2% YoY Diluted EPS
$0.14
▲ 27.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-28
Vanda Pharmaceuticals Inc. (VNDA) Q2 2021 Earnings Call Transcript
Revenue
$67.90M
▲ 9.2% YoY Diluted EPS
$0.17
▲ 6.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
Vanda Pharmaceuticals Inc. (VNDA) Q1 2021 Earnings Call Transcript
Revenue
$62.67M
▲ 8% YoY Diluted EPS
$0.15
▲ 1400% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-10
Vanda Pharmaceuticals Inc. (VNDA) Q4 2020 Earnings Call Transcript
Revenue
$67.65M
▲ 11% YoY Diluted EPS
$0.15
▲ 87.5% YoY Gross margin
90.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-28
Vanda Pharmaceuticals Inc. (VNDA) Q3 2020 Earnings Call Transcript
Revenue
$60.31M
▲ 1.4% YoY Diluted EPS
$0.11
▼ 94% YoY Gross margin
89.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
Vanda Pharmaceuticals Inc. (VNDA) Q2 2020 Earnings Call Transcript
Revenue
$62.21M
▲ 5.3% YoY Diluted EPS
$0.16
▼ 23.8% YoY Gross margin
90.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Vanda Pharmaceuticals Inc. (VNDA) Q1 2020 Earnings Call Transcript
Revenue
$58.00M
▲ 21.6% YoY Diluted EPS
$0.01
Gross margin
90.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-25
Vanda Pharmaceuticals Inc. (VNDA) Q4 2019 Earnings Call
Revenue
$60.93M
▲ 14.9% YoY Diluted EPS
$0.08
▼ 57.9% YoY Gross margin
89.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–29 of 29 webcasts